Physician profile
Mary Katherine Mcfeters
NPI 1740897065
$30,357.55
in general payments reported to CMS, 2019-2025
24 companies · $9,291 in 2025
The $9,291 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,746 · 2022: $9,019 · 2023: $6,527 · 2024: $2,774 · 2025: $9,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $1,155 · Travel and Lodging: $125 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,247.74 |
| Food and Beverage | $1,155.01 |
| Travel and Lodging | $124.62 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $27,338.08 | 2021-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $1,595.12 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $249.91 | 2021-2025 | Afrezza |
| Pfizer INC. | $156.08 | 2022-2025 | |
| Novo Nordisk INC | $137.09 | 2023-2025 | Sogroya, Wegovy, Rybelsus |
| Medtronic, INC. | $120.82 | 2022-2025 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $85.30 | 2024-2025 | |
| Tolmar, INC. | $84.26 | 2024-2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $68.17 | 2024 | Strensiq |
| Eton Pharmaceuticals, INC. | $60.73 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Sequel Med Tech, LLC | $58.99 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $58.17 | 2023 | Triptodur |
| Rhythm Pharmaceuticals, INC. | $41.85 | 2025 | Imcivree |
| Ascendis Pharma Endocrinology INC | $38.67 | 2023-2024 | |
| Embecta Corp. | $34.44 | 2023 | Bd Nano 2nd Gen Pen Needle |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.21 | 2023-2025 | |
| Zealand Pharma US, INC. | $32.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.61 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $25.70 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.95 | 2022 | |
| Endo Pharmaceuticals INC. | $22.56 | 2021 | |
| Ascensia Diabetes Care US INC. | $21.26 | 2024 | |
| Lifescan, INC. | $20.60 | 2023 | |
| Dexcom, INC. | $18.79 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcfeters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.